Compare INSM & RBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | RBA |
|---|---|---|
| Founded | 1988 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4B | 20.0B |
| IPO Year | 2000 | 1997 |
| Metric | INSM | RBA |
|---|---|---|
| Price | $123.31 | $84.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 5 |
| Target Price | ★ $201.17 | $122.20 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 1.37 |
| Revenue | N/A | ★ $4,590,700,000.00 |
| Revenue This Year | $182.31 | $4.43 |
| Revenue Next Year | $65.19 | $6.65 |
| P/E Ratio | ★ N/A | $61.37 |
| Revenue Growth | N/A | ★ 7.15 |
| 52 Week Low | $90.39 | $79.75 |
| 52 Week High | $212.75 | $119.33 |
| Indicator | INSM | RBA |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 45.52 |
| Support Level | $122.21 | $82.03 |
| Resistance Level | $130.83 | $88.69 |
| Average True Range (ATR) | 4.77 | 2.03 |
| MACD | -0.70 | 1.10 |
| Stochastic Oscillator | 59.58 | 83.64 |
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
RB Global has evolved into a leading global marketplace that connects buyers and sellers of commercial assets and vehicles. It is the result of the 2023 combination of Ritchie Bros. and IAA. Ritchie Bros.' roots were as an auctioneer facilitating transactions of commercial, construction, and transportation equipment (excavators, bulldozers, forklifts, and commercial trucks and trailers). However, it has evolved into an omnichannel marketplace. IAA has similar roots, though primarily focused on the salvage auction segment for consumer automobiles. The group provides ancillary services including title processing, transportation/towing, financing, data and appraisal, and so on. Its activities are international, though skewing approximately two-thirds to North America.